Ravinder Sodi

Ravinder Sodi

Auto-generated profile, based on publicly available information

Ravinder Sodi

Department of Biochemistry, Broomfield Hospital, Mid & South Essex NHS Foundation Trust , Chelmsford, Essex

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2018 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
STSehar Toosy
Sehar Toosy
RSRavinder Sodi
Ravinder Sodi
Joseph M. PappachanJoseph M. Pappachan
Joseph M. Pappachan

28 February 2014 in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Verified
Journal Article
Closed access
PDF file
PMP Manghat
P Manghat
RSR Sodi
R Sodi
RSR Swaminathan
R Swaminathan
Recent studies of inherited disorders of phosphate metabolism have shed new light on the understanding of phosphate metabolism. Phosphate has important functions in the body and several mechanisms have evolved to regulate phosphate balance including vitamin D, parathyroid hormone and phosphatonins such as fibroblast growth factor-23 (FGF23). Disorders of phosphate homeostasis leading to hypo- and hyperphosphataemia are common and have clinical and biochemical consequences. Notably, recent studies have linked hyperphosphataemia with an increased risk of cardiovascular disease. This review outlines the recent advances in the understanding of phosphate homeostasis and describes the causes, investigation and management of hypo- and hyperphosphataemia.

22 January 2018 in Current Hypertension Reports
Verified
Journal Article
Closed access
PDF file
Joseph M. PappachanJoseph M. Pappachan
Joseph M. Pappachan
NTNyo Nyo Tun
Nyo Nyo Tun
GAGanesan Arunagirinathan
Ganesan Arunagirinathan
RSRavinder Sodi
Ravinder Sodi
FHFahmy W. F. Hanna
Fahmy W. F. Hanna

1 September 2020 in Viruses
Verified
Journal Article
Open access
PDF file
Mohammed RohaimMohammed Rohaim
Mohammed Rohaim
Emily ClaytonEmily Clayton
Emily Clayton
ISIrem Sahin
Irem Sahin
Julianne VilelaJulianne Vilela
Julianne Vilela
MKManar Khalifa
Manar Khalifa
MMMuhammad Munir
Muhammad Munir
Until vaccines and effective therapeutics become available, the practical solution to transit safely out of the current coronavirus disease 19 (CoVID-19) lockdown may include the implementation of an effective testing, tracing and tracking system. However, this requires a reliable and clinically validated diagnostic platform for the sensitive and specific identification of SARS-CoV-2. Here, we report on the development of a de novo, high-resolution and comparative genomics guided reverse-transcribed loop-mediated isothermal amplification (LAMP) assay. To further enhance the assay performance and to remove any subjectivity associated with operator interpretation of results, we engineered a novel hand-held smart diagnostic device. The robust diagnostic device was further furnished with automated image acquisition and processing algorithms and the collated data was processed through artificial intelligence (AI) pipelines to further reduce the assay run time and the subjectivity of the colorimetric LAMP detection. This advanced AI algorithm-implemented LAMP (ai-LAMP) assay, targeting the RNA-dependent RNA polymerase gene, showed high analytical sensitivity and specificity for SARS-CoV-2. A total of ~200 coronavirus disease (CoVID-19)-suspected NHS patient samples were tested using the platform and it was shown to be reliable, highly specific and significantly more sensitive than the current gold standard qRT-PCR. Therefore, this system could provide an efficient and cost-effective platform to detect SARS-CoV-2 in resource-limited laboratories.

1 May 2004 in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Verified
Journal Article
Open access
RSRavinder Sodi
Ravinder Sodi
SDSimon M Darn
Simon M Darn
ASAnthony Stott
Anthony Stott
Background: The pneumatic tube system (PTS) has been implicated in inducing haemolysis. It is not known whether certain sample types are more susceptible to haemolysis than others. We assessed the level of haemolysis in commonly used sample types in the clinical biochemistry department when transported through the PTS. Method: Blood was collected in pairs for different sample types and sent to the laboratory via the pneumatic tube or delivered by a porter. Haemolysis indices were measured spectrophotometrically and compared for each pair of sample type. Results: Our results suggest that plain serum samples are more susceptible to haemolysis than the other sample types when sent through our PTS ( P <0.0001). Compared with serum with gel samples, plain serum samples are more prone to haemolysis ( P <0.001). This suggests that gel may confer some protection against haemolysis. Conclusion: Different hospitals will have varying system configurations and use different sample types. We recommend that each hospital investigate their own system to assess whether haemolysis is a recurring problem in any of the sample types transported.

1 January 2006 in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Verified
Journal Article
Closed access
RSRavinder Sodi
Ravinder Sodi
SDSimon M Darn
Simon M Darn
Andrew Stuart DavisonAndrew Stuart Davison
Andrew Stuart Davison
ASAnthony Stott
Anthony Stott
ASAlan Shenkin
Alan Shenkin
Background: The cardiac troponins have been shown to be sensitive and specific biochemical markers of myocardial infarction and highly prognostic for future adverse events in patients with acute coronary syndromes. There have been reports suggesting that haemolysis causes a negative interference in the cardiac troponin T (cTnT) assay but the mechanism(s) involved remain unknown. Here we show the effects of haemolysis and haemoglobin per se on the cTnT assay. Methods: The effect of haemolysis was studied by the addition of prepared haemolysate to serum samples with known and clinically relevant cTnT levels. The effect of haemoglobin was studied by the addition of haemoglobin of increasing concentrations and noting its effect on the level of cTnT measured. The effect of putative proteases was determined indirectly by incubating samples with spiked cTnT with various protease inhibitors and observing the changes in the measured cTnT levels. Results: The results show that both haemolysis, which is the release of haemoglobin and corpuscular contents, and haemoglobin itself negatively interfere in the cTnT assay in a concentration-dependent manner, although the former had a greater magnitude of effect. On haemolysis, indirect evidence suggests that proteases are released which degrade the cTnT in serum, thus causing the decreased levels detected. Pepstatin A, a reversible inhibitor of aspartic proteinases, effectively inhibited the loss of cTnT in serum at 37°C and pH 7.4 over a 48-h period. We found that at a haemoglobin level of 0.75 g/L, cTnT declined by more than 10% of the initial concentration, suggesting that falsely decreased levels due to haemolysis may significantly affect the clinical utility of the assay. Conclusions: Haemolysis, haemoglobin per se and possibly proteolysis play a role in the negative interference in cTnT assays. Measures to reduce this interference must be implemented.